SOCMA Appoints Two Executives to Second Term on Board of Governors
"I feel privileged to rejoin SOCMA's Board, especially at this crucial moment for the association," said Mielke. "SOCMA's member network has been an invaluable resource for ChemDesign, offering critical insights into legislation and EHS resources. SOCMA has also assisted us in dealing with pandemics, supply chain disruptions, tariffs, and regulations."
"As CEO of Boulder Scientific Company, I deeply appreciate SOCMA membership, offering invaluable connections to custom chemical manufacturing markets," said Preziotti. Through SOCMA, we engage with peer companies, addressing shared challenges in regulatory compliance, environmental concerns, safety, transportation, logistics, training, and labor availability. This affiliation ensures BSC's voice is heard across various forums, making SOCMA highly valuable to us."
Mielke and Preziotti will serve a three-year term ending
A complete listing of SOCMA's 2024 Board of Governors can be found here.
About SOCMA:
Solely dedicated to the specialty and fine chemical industry, the Society of Chemical Manufacturers & Affiliates® (SOCMA) builds commercial connections, supports safe manufacturing and operations, and advocates for regulatory and legislative policies for the batch and specialty chemical sector. Our members play an indispensable role in the global chemical supply chain, providing specialty chemicals and services to vital markets ranging from aerospace and electronics to pharmaceuticals and agriculture. For more information on the association, visit https://www.socma.org.
Contact:
Sr. Manager, Member Communications & Programs
571-348-5100
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/socma-appoints-two-executives-to-second-term-on-board-of-governors-302072984.html
SOURCE Society of Chemical Manufacturers & Affiliates
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Solstice Advanced Materials Declares Dividend of $0.075 per Common Share
- REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
- Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share